Annual Report 2005 - Boehringer Ingelheim

More documents

Recommendations

Info

118 Product name Active ingredient Indication mobic® mobec® movalis® movatec® motens® caldine® tens® midotens® meloxicam Symptomatic treatment of rheumatic diseases lacidipine Treatment of essential hypertension mucoangin® ambroxol hydrochloride Pain relief in acute sore throat mucosolvan® motosol® mucosan® surbronc® pharmaton® pharmaton® capsules geriavit pharmaton® pharmaton® caplets ambroxol Mucolytic treatment of acute and chronic bronchopulmonary diseases associated with impaired formation and transport of mucus standardized ginseng extract G115®, vitamins, minerals, trace elements To improve physical and mental performance and wellbeing sifrol® pramipexole Symptomatic treatment of idiophathic Parkinson’s disease silomat® clobutinol hydrochloride Symptomatic treatment of irritable, nonproductive cough spiriva® tiotropium bromide Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), the maintenance treatment of associated dyspnoea and for prevention of exacerbations thomapyrin® ASA, paracetamol, caffeine viramune® nevirapine Available as tablets for adults and suspension for children – for the combination therapy of HIV infection and for the prevention of mothertochild transmission of HIV yentreve® ariclaim® <strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 5 Pain duloxetine Moderate to severe stress urinary incontinence (SUI) in women
Animal Health Product name Active ingredient Indication buscopan® compositum Nbutyl scopolamonium bromide + metamizole enterisol® ileitis attenuated life vaccine (Lawsonia intracellularis) lyophilised express® attenuated life vaccine (IBRV, BVDV, PI3V, BRSV) ingelvac® m.hyo inactivated Mycoplasma hyopneumoniae ingelvac® prrs mlv modified live PRRS virus, grown in a permanent cell line freezedried mamyzin® penethamate hydroiodide Spasmolitic and pain inhibitor for the treatment of colic (horse and cattle) For active immunisation of pigs to reduce intestinal lesions caused by Lawsonia intracellularis infection and to reduce growth variability and loss of weight gain associated with the disease For prevention of reproductive and respiratory diseases in cattle For the active immunization of swine from three weeks of age to reduce lung lesions following infection with Mycoplasma hyopneumoniae For the active immunization of clinically healthy swine against the respiratory and reproductive form of PRRS virus infection (porcine reproductive respiratory syndrome) For the treatment of mastitis caused by Grampositive pathogens metacam® meloxicam Dog, horse: alleviation of pain and inflammation associated with acute or chronic musculoskeletal disorders Cat, dog: reduction of postoperative pain Cattle: respiratory infection, diarrhoea, acute mastitis Swine: noninfectious locomoter disorders, mastitismetritisagalacticsyndrome ventipulmin® clenbuterol Bronchodilator for the treatment of acute and chronic obstructive airway disease in horses vetmedin® pimobendan For the treatment of congestive heart failure in dogs voren® dexamethasone21isonicotinate For the treatment of metabolic disorders, inflammation and allergic reactions in cattle, swine, horses, dogs and cats Glossary 119
Page 1 and 2:
Value through Innovation Annual Rep
Page 3 and 4:
Contents 2 The Shareholders’ Pers
Page 5 and 6:
Value through Innovation Our vision
Page 7 and 8:
of innovative medications. Our expe
Page 9 and 10:
countries since 2000 encourages us
Page 11:
Shareholders’ Committee Dr Heribe
Page 14 and 15:
10 Our commitment We have committed
Page 16 and 17:
1 For our neighbours We are fundame
Page 18 and 19:
1 For our people To achieve our cor
Page 20 and 21:
1 We foster good leadership at all
Page 22 and 23:
1 For our environment In all our ac
Page 24 and 25:
0 Assessments to date show that our
Page 27 and 28:
Our R&D drive Holger Pfister has be
Page 29 and 30:
New data presented at the 10th Euro
Page 31 and 32:
Thanks to new treatments and innova
Page 33 and 34:
Laboratory assistants at our Qualit
Page 35 and 36:
In addition, our discovery efforts
Page 37 and 38:
the age of 65 combined with an agin
Page 39 and 40:
Clinical development and registrati
Page 41 and 42:
increase the planned patient number
Page 43:
Business Development Our Businesses
Page 46 and 47:
“spiriva® has obviously improved
Page 48 and 49:
Prescription Medicines Boehringer I
Page 50 and 51:
Protection around the clock “In t
Page 52 and 53:
Stroke treatment and prevention Str
Page 54 and 55:
0 Serotonin and norepinephrine also
Page 56 and 57:
Rheumatologic diseases Osteoarthrit
Page 58 and 59:
Asia, Australasia, Africa In all ma
Page 60:
Consumer Health Care Let’s talk a
Page 63 and 64:
Gentle and effective dulcolax® for
Page 65 and 66:
health market. With sales of almost
Page 67 and 68:
is critical
Page 69 and 70:
at the end of the 1970s with the ma
Page 71 and 72: Moreover, for Boehringer Ingelheim
Page 73 and 74: Pioneering college course in biotec
Page 75 and 76: heartWhen her Labrador Buster fell
Page 77 and 78: According to the American Veterinar
Page 79 and 80: Cattle There were two highly gratif
Page 81 and 82: Group Management Report
Page 83 and 84: and strength of the group. The grea
Page 85 and 86: cymbalta®, the anti-depressive in-
Page 87 and 88: Components of growth in net sales (
Page 89 and 90: Worldwide growth was achieved by th
Page 91 and 92: Liquid assets declined by 12 % comp
Page 93 and 94: Consolidated Financial Statements 2
Page 95 and 96: C. H. Boehringer Sohn Grundstücksv
Page 97 and 98: C. H. Boehringer Sohn, Ingelheim Co
Page 99 and 100: C. H. Boehringer Sohn, Ingelheim St
Page 101 and 102: The following subsidiaries were exe
Page 103 and 104: 2 Accounting and evaluation methods
Page 105 and 106: 3 Notes to the consolidated balance
Page 107 and 108: 3.3 Financial assets (in millions o
Page 109 and 110: Pension provisions Boehringer Ingel
Page 111 and 112: 4 Notes to the consolidated profit
Page 113 and 114: 4.7 Holding income (in millions of
Page 115 and 116: Other mandatory disclosures accordi
Page 117 and 118: Derivative financial instruments at
Page 119 and 120: With the following exception, our a
Page 121: Product name Active ingredient Indi
Page 125 and 126: Comparison of Balance Sheets/ Finan
show all

Annual Report 2005 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?